Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Natural History of Post-Coronavirus Disease 19 Convalescence at the National Institutes of Health

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04573062
Recruitment Status : Recruiting
First Posted : October 5, 2020
Last Update Posted : October 1, 2021
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Institute of Neurological Disorders and Stroke (NINDS) )

Tracking Information
First Submitted Date October 1, 2020
First Posted Date October 5, 2020
Last Update Posted Date October 1, 2021
Actual Study Start Date October 15, 2020
Estimated Primary Completion Date December 31, 2024   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: September 29, 2021)
  • Screening Phase [ Time Frame: End of Study ]
    The number and severity of persistent symptoms associated with COVID-19 convalescence. Collected data will be used to characterize different narratives of COVID-19 convalescence.
  • Phase C: Deep Phenotyping [ Time Frame: End of Study ]
    Phase C:Characterization of the immune system and inflammatory signaling in collected samples at baseline and following maximal exercise exertion using flow cytometry of blood and cerebrospinal fluid, RNA sequencing of PBMC subtypes, multiplex immunochemical analysis, NK cell functional analysis. Characterization of the pattern of microbiome in collected samples at baseline and following maximal exercise exertion using Shotgun metagenomics of bacterial genetic material. Characterization of bioenergetics, autonomic, and metabolic function in collected samples at baseline and following maximal exercise exertion using Mitochondrial plasmid genotyping, pulmonary spirometry, gas exchange measurements during exercise, metabolic chamber measurements of total body energy use, metabolomic analysis of stool, mitochondrion proteomics and metabolomics from muscle, and functional respiration of PBMCs using extracellular flux mito stress assay.
  • Phase B: Evaluation [ Time Frame: End of Study ]
    Phase B: Standard clinical and research evaluations will be used to measure cardiopulmonary, neurological, and functional status and identify individuals with unknown PASC.
Original Primary Outcome Measures
 (submitted: October 1, 2020)
Screening Phase [ Time Frame: End of Study ]
The number and severity of persistent symptoms associated with COVID-19 convalescence. Collected data will be used to characterize different narratives of COVID-19 convalescence.
Change History
Current Secondary Outcome Measures Not Provided
Original Secondary Outcome Measures Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Natural History of Post-Coronavirus Disease 19 Convalescence at the National Institutes of Health
Official Title Natural History of Post-Coronavirus Disease 19 Convalescence at the National Institutes of Health
Brief Summary

Background:

People who get COVID-19 have a wide range of symptoms. They also recover from COVID-19 in different ways. In this study, researchers will use survey data to describe the different ways people experience and recover from COVID-19. They will also use the data to help create future studies to understand why some people do not fully recover.

Objective:

To learn more about the range and timing of symptoms that people have before, during, and after COVID-19 infection.

Eligibility:

People ages 18 and older who can give documentation of a positive COVID-19 or antibody test.

Design:

Participants will be screened with a telephone interview. It will take 15 minutes. They will provide their COVID-19 test results and medical records.

Participants will complete a second telephone interview. It will take 30 60 minutes. They will also take online surveys every 3 months for 3 years.

The interview and surveys will ask participants about their health before they got COVID-19, what happened while they had COVID-19, and what their recovery has been like.

Participants will get log-in data to take the online surveys. Completing all of the surveys the first time may take up to 3 hours. Follow-up surveys will take up to 30 minutes. Participants do not have to complete the surveys in one sitting. They will be able to save their progress and finish the surveys later.

Participants may be contacted to take part in other research studies.

Detailed Description

Title: Natural History of Post-Coronavirus Disease 19 Convalescence at the National Institutes of Health

Study Description: In late 2019, the novel coronavirus SARS/CoV2 appeared in Wuhan, China. The various ways that humans will recover from COVID-19 is just starting to be observed and it is clear there will be a wide range of convalescent experiences. A year into the pandemic, the post-acute sequelae of SARS/CoV2 infection (PASC) is known to be common and includes a broad range of symptoms and potential pathologies. This phased protocol is designed to observe and study the convalescence and recoveries from acute SARS/CoV2 infections.

Phase A Phase A Surveying (Phase A) will enable people in the community that are convalescing from COVID-19 to be studied

using telephone interviews and internet-based questionnaires. The objective of Phase A Surveying is to observe and describe the range of medical syndromes that occur in the wake of an acute SARS/CoV2 infection. Participants are required to be within the first six months of their recovery and have documentation of a positive laboratory test for COVID-19. .Additional cohorts of persons with neurological sequelae, persons with a clinical diagnosis of COVID-19 with negative testing, and participants co-enrolled in other research studies within the Division of Intramural Research will also be studied. The data collected during Phase A will describe the range of symptoms and patterns of symptom clustering of PASC. This data will also characterize the patient populations which have been or will be evaluated at the NIH Clinical Center in more detail.

Phase B Evaluation (Phase B) will allow surveyed participants of research interest from Phase A to be invited to the NIH Clinical Center for a medical evaluation and to undergo a panel of standard research measurements. Each participant will be medically and psychologically characterized to best understand if their complaints can be attributed to known disorders. The observations made during Phase B will provide insights into the range, character, and subtypes of PASC. Individuals found to have disorders being studied within the Division of Intermural Research at NIH will be appropriately

referred. Evaluated individuals with persistent symptoms in the absence of demonstrable medical disease and individuals who fully recovered from SARS/CoV2 will be invited back to the NIH Clinical Center for broad and deep research measurements Phase C Deep Phenotyping (Phase C)employed will be synchronized with other NIH-approved deep phenotyping protocols to foster crossphenotype comparison research with other medical syndromes, such as Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Gulf War Illness (GWI). Deep phenotyping characterizations would be used to generate scientific hypotheses for testing in future studies and for cross-comparisons with other fatiguing disorders. Evaluated individuals with PASC may be invited to participate in Phase D Longitudinal Evaluation phase (Phase D). This would enable the observation of the natural history of PASC and allow for exploration of the biological mechanisms underlying successful

recovery and how recovery can go awry. Previous epidemics have created unique medical syndromes in the past. Data from this protocol may be used to characterize PASC and any Post-COVID 19 Syndrome subtypes that may be discovered. If warranted, a Criteria Development phase will develop data-driven research consensus criteria for defining PASC and any Post-COVID

19 Syndromes.

The results of this protocol will provide novel insights into COVID- 19 convalescence and its potential outcomes.

This current version of the protocol provides the details for Phase A, Phase B, and Phase C. Additional phases will be detailed in planned protocol amendments.

Study Type Observational
Study Design Observational Model: Case-Only
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population 1540 persons who are recovering from an acute COVID-19 infection will participate. Individuals in the community who are within six months of their convalescence from an acute COVID-19 infection. 250 adults recovering from neurological sequelae from a COVID-19 infection that may be eligible for participation in Protocol 00094 An Observational Study of Neurological Function After COVID 19 Infection 50 adults with medical documentation supporting a clinical diagnosis of a COVID-19 infection with negative or absent PCR testing and negative antibody testing.
Condition Post-Coronavirus Disease 19
Intervention Not Provided
Study Groups/Cohorts Post COVID patients
Individuals whom have previously had COVID -19 infection.
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Recruiting
Estimated Enrollment
 (submitted: May 13, 2021)
1540
Original Estimated Enrollment
 (submitted: October 1, 2020)
1000
Estimated Study Completion Date December 31, 2024
Estimated Primary Completion Date December 31, 2024   (Final data collection date for primary outcome measure)
Eligibility Criteria
  • INCLUSION CRITERIA:

For Phase A Surveying:

1540 persons who are recovering or have recoverred from an acute SARS/CoV2 infection will participate.

Inclusion criteria for Phase A:

Post-COVID-19 Convalescence (n=1000)

  • Participants 18 and older
  • Ability to provide informed consent
  • Stated willingness to complete telephone interviews
  • Reports having begun recovery from an acute SARS/CoV2 infection within the last six months
  • Provides documentation of a positive COVID-19 PCR. A positive antibody test is also accepted in unvaccinated individuals.

OR

Post-COVID-19 Neurological Sequelae (n=250)

  • Participants 18 and older
  • Ability to provide informed consent
  • Stated willingness to complete telephone interviews
  • Reports having developed neurological symptoms as a consequence of an acute SARS/CoV2 infection
  • Provides documentation of a positive COVID-19 PCR. A positive antibody test is also accepted in unvaccinated individuals.

OR

Test-Negative COVID-19 with Persistent Symptoms (n=50)

  • Participants 18 and older
  • Ability to provide informed consent
  • Stated willingness to complete telephone interviews
  • Reports having developed persistent symptoms as a consequence of an acute SARS/CoV2 infection
  • Provides documentation of a clinical diagnosis of an acute SARS/CoV2 infection from a medical practitioner OR meets the Clinical Criteria of the 2020 CDC Interim Case Definition for Probable SARS/CoV2 infection.
  • Has either negative or absent COVID-19 PCR testing for the documented SARS/CoV2 infection.
  • Provides documentation of a negative COVID-19 antibody test.

OR

Participants enrolled in protocol 20CC0113: Cardiopulmonary Inflammation and Multi- System Imaging During the Clinical Course of COVID-19 Infection in Asymptomatic and Symptomatic Persons (N=150)

  • Participants 18 and older
  • Ability to provide informed consent
  • Stated willingness to complete telephone interviews
  • Provides documentation of a positive COVID-19 PCR or antibody test 5.

Co-enrollment in 20CC0113

OR

Participants enrolled in protocol 000102-CC: COVID-19, Chronic Adaptation, and Response to Exercise (COVID-CARE) (N=90)

  • Participants 18 and older
  • Ability to provide informed consent
  • Stated willingness to complete telephone interviews
  • Provides documentation of a positive COVID-19 PCR or antibody test
  • Co-enrollment in 000102-CC

The elements of the 2020 CDC Interim Case Definition for Probable COVID-19 used for this protocol will be the Clinical Criteria:

Clinical Criteria:

At least two of the following symptoms: fever (measured or subjective), chills, rigors, myalgia, headache, sore throat, new olfactory and taste disorder(s)

OR

At least one of the following symptoms: cough, shortness of breath, or difficulty breathing

OR

Severe respiratory illness with at least one of the following:

  • Clinical or radiographic evidence of pneumonia, OR
  • Acute respiratory distress syndrome (ARDS).

AND

No alternative more likely diagnosis.

For Phase B Evaluation:

22040 persons who are recovering or have recovered from COVID-19 within the last six months will participate.

Inclusion Criteria for all Phase B participants:

  • Adult participants aged 18-60 years at the time of enrollment.
  • Self-reported completion of at least the 7th grade of school.
  • Fluency in English.
  • Willing and able to complete all study procedures
  • Participant has a primary care provider at the time of enrollment.
  • Able to provide informed consent
  • Participants must be at least six weeks out since the onset of COVID-19 symptom with no fever for at least one week.
  • Participants must be within six months since starting to recover from acute COVID-19 symptoms. The date of the start of recovery can be determined by:

    • The date that fever broke for the first time
    • The date the participant recalls starting to improve

If a participant is unable to report a reliable date, a date of six weeks from the onset of COVID-19 symptoms may be imputed.

Does not have an active SARS-CoV-2 infection. The protocol will conform with NIH CC standards for documenting a participant does not have active SARS-CoV-

-infection. This may include screening interviews and/or testing.

Inclusion Criteria for Mild to Moderate Illness COVID-19 with severe PASC symptoms:

  • Licensed Independent Practitioner documentation of a stable state of general wellhealth and physical function prior to contracting SARS-CoV-2. This may include medical records, correspondence letters, or information gathered from telephone calls with study personnel.
  • A self-reported illness narrative of the development of persistent PASC symptoms after recovering from a SARS-CoV-2 infection. These include symptoms such as fatigue, cognitive difficulties, orthostatic intolerance, unrefreshing sleep, neuropathic pain, mood change, and post-exertional malaise.
  • Laboratory documentation of a positive PCR test for COVID-19 at the time of the SARS-CoV-2 infection.
  • Meets WHO Clinical Progression Scale[45] of 2 - 6:

    • Ambulatory; symptomatic, independent
    • Ambulatory; symptomatic, assistance needed
    • Hospitalized; no oxygen therapy
    • Hospitalized; oxygen by mask or nasal prongs
    • Hospitalized; oxygen by non-invasive ventilation or high flow oxygen
  • Functional Criteria: Substantial symptom severity as determined using SF-36v2: score of <=70 physical function subscale, or <=50 on role physical subscale, or <=75 on social function subscale.

Inclusion Criteria for Mild or Moderate Illness COVID-19 without PASC symptoms:

  • Licensed Independent Practitioner documentation of a stable state of general well health and physical function prior to contracting SARS-CoV-2. This may include medical records, correspondence letters, or information gathered from telephone calls with study personnel.
  • A self-reported illness narrative of recovery to prior health after a SARS/CoV2 infection.
  • Laboratory documentation of a positive PCR test for COVID-19 at the time of the SARS-CoV-2 infection.
  • Meets WHO Clinical Progression Scale of 2 - 6:

    • Ambulatory; symptomatic, independent
    • Ambulatory; symptomatic, assistance needed
    • Hospitalized; no oxygen therapy
    • Hospitalized; oxygen by mask or nasal prongs
    • Hospitalized; oxygen by non-invasive ventilation or high flow oxygen

Functional Criteria: No substantial symptom severity as determined using SF-36v2: score of >=85 physical function subscale, and >=85 on role physical subscale, and >= 85 on social function subscale.[46]

Inclusion Criteria for Mild or Moderate Illness COVID-19 with mild to moderate PASC symptoms:

  • Licensed Independent Practitioner documentation of a stable state of general well health and physical function prior to contracting SARS-CoV-2. This may include medical records, correspondence letters, or information gathered from telephone calls with study personnel.
  • Either a self-reported illness narrative of near recovery to prior health or a narrative of the development of persistent PASC symptoms after recovering from a SARS-CoV-2 infection. These include symptoms such as fatigue, cognitive difficulties, orthostatic intolerance, unrefreshing sleep, neuropathic pain, mood change, and post-exertional malaise.
  • Laboratory documentation of a positive PCR test for COVID-19 at the time of the SARS-CoV-2 infection.
  • Meets WHO Clinical Progression Scale of 2 - 6:

    • Ambulatory; symptomatic, independent
    • Ambulatory; symptomatic, assistance needed
    • Hospitalized; no oxygen therapy
    • Hospitalized; oxygen by mask or nasal prongs
    • Hospitalized; oxygen by non-invasive ventilation or high flow oxygen
  • Functional Criteria: Mild to moderate symptom severity as determined using SF-36v2: score of between 71 and 84 on the physical function subscale, or between 51 and 84 on role physical subscale, or between 76 and 84 on social function subscale.

For Phase C Deep Phenotyping:

Inclusion Criteria for Mild to Moderate Illness COVID-19 with PASC symptoms (unknown PASC):

-Met inclusion and exclusion criteria for Mild to Moderate Illness COVID-19 with severe post-acute COVID-19 symptoms after completing Phase B.

No alternative explanation for PASC symptoms identified by adjudication committee during Phase B.

-Fluency in English

Inclusion Criteria for Mild or Moderate Illness COVID-19 without PASC symptoms:

  • Met inclusion and exclusion criteria for Mild to Moderate Illness COVID-19 without post-acute COVID-19 symptoms after completing Phase B.
  • Fluency in English

EXCLUSION CRITERIA:

Exclusion criteria for Phase A:

  • Not willing to provide personal identifying information to investigative team
  • Cognitive impairment that is severe enough to limit consent capacity

Exclusion criteria for Phase B Evaluation:

Information collected from Phase A interviews, review of medical records, and discussions with consented Phase A participants will be used to determine if a participant will be excluded from participation.

  • Current or past psychotic disorder including depression with psychosis, bipolar disorder with psychotic symptoms and schizophrenia
  • Major depression disorder, generalized anxiety disorder, post-traumatic stress disorder, panic disorder, or obsessive-compulsive disorder unless managed for more than six months with a stable treatment regimen
  • Current or past substance use disorder within last five years. Marijuana use within the past five years will not be an exclusion.
  • History of head injury leading to moderate or severe traumatic brain injury. Persons having a history of mild TBI (mTBI) will not be excluded.
  • Women who are pregnant, breastfeeding, or are within one-year post-partum.
  • Current or previous malignancy. A history of malignancy that has fully resolved with surgical resection only (e.g. no chemotherapy, radiation therapy, or immunotherapy) will be allowed.
  • Current systemic immunologic disorders (e.g. Type 1 diabetes, rheumatoid arthritis).

Local immunological disorder (e.g. atopic dermatitis, stable autoimmune thyroid disease) and allergic disorders will be allowed.

  • Current or previous long-term immune suppressive therapy. Recent or current steroid use for the treatment of COVID-19, PASC, recent allergic reactions, and topical steroid use is allowed.
  • Any premorbid medical condition that would potentially cause fatigue and exercise intolerance that would exclude from participation in Phase C. This includes many chronic medical diseases, such as congestive heart failure, coronary artery disease, chronic obstructive pulmonary disease, severe arthritis, uncontrolled asthma, renal failure, fibromyalgia, and ME/CFS.
  • Active participation in a clinical protocol (e.g. anti-inflammatory drug intervention study) which includes an intervention that may affect the results of the current study.
  • Not willing to allow for research data and samples to be shared broadly with other researchers.
  • Employees at NIH that are under the direct supervision of the study investigators.
  • Symptom severity that makes it impossible for the volunteer to travel to NIH.

Exclusion criteria for Phase C Deep Phenotyping:

Exclusion criteria for all Phase C participants:

  • Current or past psychotic disorder including depression with psychosis, bipolar disorder with psychotic symptoms and schizophrenia
  • Current DSM-5-defined major depression disorder, generalized anxiety disorder, posttraumatic stress disorder, panic disorder, or obsessive-compulsive disorder unless managed for more than six months with a stable treatment regimen
  • Current or past substance use disorder within last five years as diagnosed on the Structured Clinical Interview for DSM-5 (SCID-5). Marijuana use will not be an exclusion.
  • Use of opiates, cocaine, or benzodiazepines as seen on urine toxicology screening.
  • Current suicidal ideation
  • History of head injury leading to moderate or severe traumatic brain injury, as detailed by loss of consciousness for greater than 30 minutes, a Glasgow Coma Score of 12 or less at the time of injury, post-traumatic amnesia greater than one day, or brain-scan changes related to a head injury. Persons having a history of mild TBI (mTBI) will not be

excluded.

  • Women who are pregnant, breastfeeding, or are within one-year post-partum.
  • Current or previous malignancy. A history of malignancy that has fully resolved with surgical resection only (e.g. no chemotherapy, radiation therapy, or immunotherapy) will be allowed.
  • Current systemic immunologic disorders (e.g. Type 1 diabetes, rheumatoid arthritis). Local immunological disorder (e.g. atopic dermatitis, stable autoimmune thyroid disease) and allergic disorders will be allowed.
  • Current or previous long-term immune suppressive therapy. Systemic steroid use, even short-term, must not have been used within the month prior to enrollment
  • Any premorbid medical condition that would potentially cause fatigue and exercise intolerance or increases the risks of participation in Phase C. This includes many chronic medical diseases, such as congestive heart failure, coronary artery disease, chronic obstructive pulmonary disease, severe arthritis, uncontrolled asthma, renal failure, fibromyalgia, and ME/CFS.
  • Active participation in a clinical protocol (e.g. anti-inflammatory drug intervention study) which includes an intervention that may affect the results of the current study.
  • Inability to perform the bicycling exercise task. (e.g. coronary artery disease, not having a lower limb, disabling stroke)
  • Not willing to allow for research data and samples to be shared broadly with other researchers.
  • Employees at NIH that are under the direct supervision of the study investigators.
  • Symptom severity that makes it impossible for the volunteer to travel to NIH for an extended inpatient evaluation
  • Use of medications with a high-risk for withdrawal-related complications (i.e. long-acting opiates or benzodiazepines).
Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts
Contact: Angelique Gavin (301) 402-0880 angelique.gavin@nih.gov
Listed Location Countries United States
Removed Location Countries  
 
Administrative Information
NCT Number NCT04573062
Other Study ID Numbers 10000089
000089-N
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement Not Provided
Responsible Party National Institutes of Health Clinical Center (CC) ( National Institute of Neurological Disorders and Stroke (NINDS) )
Study Sponsor National Institute of Neurological Disorders and Stroke (NINDS)
Collaborators Not Provided
Investigators
Principal Investigator: Avindra Nath, M.D. National Institute of Neurological Disorders and Stroke (NINDS)
PRS Account National Institutes of Health Clinical Center (CC)
Verification Date September 28, 2021